Kyverna Therapeutics (KYTX) Research & Development (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Research & Development data on file, last reported at $30.1 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 19.66% year-over-year to $30.1 million; the trailing twelve-month figure through Mar 2026 stood at $126.4 million (down 0.84% YoY), and the FY2025 full-year result was $133.7 million, up 18.89% from the prior year.
• Research & Development for Q1 2026 stood at $30.1 million, roughly flat from $30.0 million in the prior quarter.
• Across five years, Research & Development topped out at $37.4 million in Q1 2025 and bottomed at $8.7 million in Q1 2023.
• The 4-year median for Research & Development is $29.2 million (2024), against an average of $25.1 million.
• The widest annual swing landed in 2024, when Research & Development surged 162.58%; it then dropped 19.66% in 2026.
• A 4-year view of Research & Development shows it stood at $17.2 million in 2023, then soared by 95.09% to $33.5 million in 2024, then retreated by 10.36% to $30.0 million in 2025, then increased by 0.2% to $30.1 million in 2026.
• The last three Research & Development figures came in at $30.1 million (Q1 2026), $30.0 million (Q4 2025), and $30.5 million (Q3 2025), per Business Quant data.

Peer Comparison